PharmaCyte Biotech Inc (PMCB)

[1234jklm]

Tbone, I think the problem with ir is that kw is ir.


And he really doesn’t understand medicine.

But Professor Gunzberg does.

And so does Dr Lohr.

And Crabtree.

But kw is the voice and kw answers ir emails and he answers like a lawyer and not a doctor or scientist. He never gives a straight answer and kind of generalizes. And he doesn’t care about shareholders so the emails sound like he’s covering his bases but not really answering. Which leads to lots of confusion.

It’s like he’s already retired.

I have found emails from ir unreliable and inconsistent. They are often contradictory to what we later find out in the conference call.

My impression is that kw doesn’t give a damn about shareholders and doesn’t bother much with the email replies. Sometimes doesn’t even answer if the questions are too tough.

But I hope Gunzberg is driving the show with kw up front holding the wheel and then I think we might be ok.

I think the technology is excellent but the communications are hopeless.

Let’s hope we get bought out soon so the technology can really have a chance.

Shouldn’t be long till Eurofins cells get the all clear.

Then pps will move up.